Not sure where to start? Try searching for your diagnosis above or visit the "Conditions" section.
Autoimmune Archive is a curated library of research, news, and resources for people living with autoimmune diseases. We track the latest studies, organize information by condition, and cut through the noise so you can spend less time searching and more time focused on your health.
Use the search bar above to find information about your diagnosis, browse the Conditions section for condition-specific resources, or explore the Library for the latest research and news. If you know of an article or resource that belongs here, we'd love to hear about it — use the Suggest a Resource link above to submit it for review.
Discover what's on this website and how to best use it.
Learn about autoimmune diseases, their symptoms, treatments, prognosis, and more.
Tools and resources to help you learn about your autoimmune disease and manage it.
The Graves' Disease Self-Advocacy Planner — Trackers, logs, and reference tools to help you unders...
View Product
The Hashimoto's Self-Advocacy Planner is a 14-form fillable PDF kit designed to help you track sympt...
View Product
18 fillable PDF forms and a guide to help you document your MS history, track your symptoms, and wal...
View Product
The Rheumatoid Arthritis Self-Advocacy Planner — 16 fillable PDF forms to help you track joint act...
View Product
The Type 1 Diabetes Self-Advocacy Planner — 16 fillable PDF forms to help you track blood sugar pa...
View ProductThe European Commission has approved AbbVie's Rinvoq (upadacitinib) for both severe alopecia areata and non-segmental vitiligo, making it the first systemic medicine cleared in the...
Read More — AbbVie's Rinvoq Wins EU Approval for Alopecia Areata and Vitiligo »Amgen has submitted new data to the FDA defending TAVNEOS (avacopan), a drug for the rare autoimmune condition ANCA-associated vasculitis, after regulators proposed pulling it from...
Read More — Amgen Fights FDA Proposal to Pull ANCA Vasculitis Drug TAVNEOS From the Market »Health Canada approved Novartis's atrasentan (Vanrafia) to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression, giving Canadian patients...
Read More — Health Canada Clears New Kidney Drug for IgA Nephropathy »The Foundation for the National Institutes of Health added scleroderma to its AMP AIM research collaboration, backed by more than $9 million in new funding, joining rheumatoid arth...
Read More — Scleroderma Joins Major Cross-Disease Autoimmune Research Initiative »Teva and Polpharma Biologics have struck a global licensing deal for a proposed biosimilar version of Ocrevus, the widely used multiple sclerosis infusion therapy, that could event...
Read More — Teva and Polpharma Ink Global Deal for an Ocrevus Biosimilar in Multiple Sclerosis »The FDA has approved atacicept (Trutakna), a new antibody-blocking drug for the autoimmune kidney disease IgA nephropathy, after it reduced protein leakage into urine by 46 percent...
Read More — FDA Approves Atacicept (Trutakna) for IgA Nephropathy »
Blog
Fatigue is one of the most persistent and frustrating symptoms for people with Hashimoto's thyroiditis, and it doesn't always resolve fully with thyroid hormone optimization alone....
Read More — Best Magnesium Supplements for Hashimoto's Thyroiditis »
Blog
Your rheumatologist calls out a number every visit, but rarely explains what it means. DAS28 measures joint tenderness, swelling, inflammation markers, and how you've been feeling...
Read More — What Is DAS28 and Why Does My Rheumatologist Use It? »
Blog
Managing Hashimoto's thyroiditis often feels like assembling a puzzle with too many pieces. Thyroid medication is typically the foundation of treatment, but many patients continue...
Read More — Best Supplements for Hashimoto's Thyroiditis: What the Evidence Actually Says »A new antibody called bempikibart produced meaningful hair regrowth in a small trial of adults with severe alopecia areata, including some patients who kept their results even afte...
Read More — Experimental Antibody Shows Durable Hair Regrowth in Severe Alopecia Areata Trial »Ipsen's elafibranor (Iqirvo) normalized a key liver enzyme in 85% of primary biliary cholangitis patients with milder disease in a new phase 3b trial, potentially doubling the numb...
Read More — PBC Liver Drug Nearly Doubles Its Potential Patient Pool in New Trial »Q32 Bio's bempikibart helped 40% of severe alopecia areata patients regrow enough hair to cover most of the scalp by week 36, offering a potential non-JAK-inhibitor alternative for...
Read More — Bempikibart Shows Durable Hair Regrowth in Severe Alopecia Areata »Scientists presented early results from a first-in-human trial testing whether engineered, lab-grown insulin-producing cells can survive in people with type 1 diabetes without life...
Read More — First-in-Human Trial Tests Immune-Engineered Cells for Type 1 Diabetes Without Lifelong Immunosuppression »A first-in-human study presented at ISSCR 2026 tests whether genetically engineered insulin-producing cells can survive in the body without lifelong immunosuppressive drugs, tackli...
Read More — A New Approach to Diabetes Cell Therapy Skips the Immunosuppression Problem »Aurinia Pharmaceuticals has launched a new study testing whether pairing its approved lupus nephritis drug with one of three newer biologics can push more patients into complete ki...
Read More — A Combination Approach to the Toughest Lupus Kidney Cases »
